Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer
© 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery..
Purpose: The NY-ESO-1 antigen is highly immunogenic and often spontaneously induces an immune response in patients with cancer. We conducted a large-scale multicenter cohort study to investigate the utility of serum NY-ESO-1 and p53 antibodies as predictive markers for the postoperative recurrence of gastric cancer. Here, we examined the usefulness of pre-treatment NY-ESO-1 and p53 antibodies as tumor markers for the diagnosis of gastric cancer in combination with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
Methods: A total of 1031 patients with cT3-4 gastric cancer were enrolled in the study. NY-ESO-1 and p53 antibodies were assessed prior to treatment. The positivity of NY-ESO-1 and p53 antibodies, CEA, and CA19-9 was evaluated before treatment.
Results: Serum NY-ESO-1 and p53 antibodies were positive in 12.6% and 18.1% of the patients, respectively. Positive NY-ESO-1 antibody response was correlated with male gender, higher cStage, and upper tumor location. However, a positive p53 antibody response was not associated with tumor factors. The combination of NY-ESO-1 or p53 antibody response with CEA and CA19-9, or the 4-factors, was positive in 45.1%, 49.6%, and 53.8% of patients, respectively. Moreover, the 4-factor combination was able to detect >60% of cStage III-IV diseases, which was 14% higher than that with the combination of CEA and CA19-9.
Conclusion: The combination of NY-ESO-1 and p53 antibody responses to CEA and CA19-9 increases the diagnostic accuracy of gastric cancer. Serum NY-ESO-1 and p53 antibodies may be useful tumor markers for gastric cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Annals of gastroenterological surgery - 8(2024), 2 vom: 01. März, Seite 243-250 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawada, Junji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody response |
|---|
| Anmerkungen: |
Date Revised 26.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ags3.12757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369452313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369452313 | ||
| 003 | DE-627 | ||
| 005 | 20240426233848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ags3.12757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM369452313 | ||
| 035 | |a (NLM)38455491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawada, Junji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery. | ||
| 520 | |a Purpose: The NY-ESO-1 antigen is highly immunogenic and often spontaneously induces an immune response in patients with cancer. We conducted a large-scale multicenter cohort study to investigate the utility of serum NY-ESO-1 and p53 antibodies as predictive markers for the postoperative recurrence of gastric cancer. Here, we examined the usefulness of pre-treatment NY-ESO-1 and p53 antibodies as tumor markers for the diagnosis of gastric cancer in combination with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) | ||
| 520 | |a Methods: A total of 1031 patients with cT3-4 gastric cancer were enrolled in the study. NY-ESO-1 and p53 antibodies were assessed prior to treatment. The positivity of NY-ESO-1 and p53 antibodies, CEA, and CA19-9 was evaluated before treatment | ||
| 520 | |a Results: Serum NY-ESO-1 and p53 antibodies were positive in 12.6% and 18.1% of the patients, respectively. Positive NY-ESO-1 antibody response was correlated with male gender, higher cStage, and upper tumor location. However, a positive p53 antibody response was not associated with tumor factors. The combination of NY-ESO-1 or p53 antibody response with CEA and CA19-9, or the 4-factors, was positive in 45.1%, 49.6%, and 53.8% of patients, respectively. Moreover, the 4-factor combination was able to detect >60% of cStage III-IV diseases, which was 14% higher than that with the combination of CEA and CA19-9 | ||
| 520 | |a Conclusion: The combination of NY-ESO-1 and p53 antibody responses to CEA and CA19-9 increases the diagnostic accuracy of gastric cancer. Serum NY-ESO-1 and p53 antibodies may be useful tumor markers for gastric cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NY‐ESO‐1 | |
| 650 | 4 | |a antibody response | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a p53 | |
| 650 | 4 | |a tumor marker | |
| 700 | 1 | |a Saito, Takuro |e verfasserin |4 aut | |
| 700 | 1 | |a Kurokawa, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabata, Ryohei |e verfasserin |4 aut | |
| 700 | 1 | |a Takeno, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Takeoka, Tomohira |e verfasserin |4 aut | |
| 700 | 1 | |a Nose, Yohei |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Hisashi |e verfasserin |4 aut | |
| 700 | 1 | |a Eguchi, Hidetoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Yuichiro |e verfasserin |4 aut | |
| 700 | 0 | |a Osaka University Clinical Research Group for Gastroenterological Study |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of gastroenterological surgery |d 2017 |g 8(2024), 2 vom: 01. März, Seite 243-250 |w (DE-627)NLM285082434 |x 2475-0328 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:2 |g day:01 |g month:03 |g pages:243-250 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ags3.12757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 2 |b 01 |c 03 |h 243-250 | ||